Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia

Savitha Varatharajan, Ajay Abraham, Wei Zhang, R. V. Shaji, Rayaz Ahmed, Aby Abraham, Biju George, Alok Srivastava, Mammen Chandy, Vikram Mathews, Poonkuzhali Balasubramanian*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Purpose The present study aimed to investigate the role of expression of daunorubicin-metabolizing enzymes carbonyl reductase 1 and 3 (CBR1 and CBR3) on the in vitro cytotoxicity of daunorubicin in primary acute myeloid leukemia (AML) cells and the effect of genetic variants in CBR1 and CBR3 on the plasma pharmacokinetics of daunorubicin and daunorubicinol (DOL) in AML patients. Methods RNA expression of CBR1 and CBR3, intracellular daunorubicin and DOL levels, and in vitro cytotoxicity of daunorubicin were measured in bone marrow mononuclear cells of 104 adult AML patients. Plasma pharmacokinetics of daunorubicin and DOL was measured in 24 patients receiving daunorubicin-based induction chemotherapy for AML. Results Increased expression of CBR1 significantly reduced the in vitro cytotoxicity of daunorubicin and also positively correlated with intracellular DOL levels. Polymorphisms in CBR1 and CBR3 did not show any association with intracellular daunorubicin or DOL levels, but there was a trend towards significant increase in plasma daunorubicin systemic exposure in patients with a variant genotype for CBR1 polymorphism rs25678. Conclusions This pilot study suggests that CBR1 RNA expression may be helpful in identifying AML patients at risk of developing resistance or toxicity to daunorubicin due to increased formation of DOL. Further confirmation of these findings in a larger sample pool would be required to determine the applicability of these results. Inhibition of CBR1 can be an option to improve the efficacy and prevent toxicity related to the treatment. Influence of daunorubicin and DOL plasma levels on clinical outcome, if any, remains to be evaluated.

Original languageEnglish (US)
Pages (from-to)1577-1586
Number of pages10
JournalEuropean Journal of Clinical Pharmacology
Volume68
Issue number12
DOIs
StatePublished - Dec 2012

Keywords

  • Acute myeloid leukemia
  • CBR1
  • CBR3
  • Carbonyl reductase
  • Daunorubicin
  • Polymorphism

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this